The technology is extremely adaptable and should efficiently incorporate any sequence into any genome. There are no direct competing solutions of similar genetic tools on the market today. This technology can be rapidly marketable and has the propensity to procure a similar or perhaps greater market share than the CRISPR-Cas9 technology.
The RACeR-tool can be sold as either a supplemental kit or a stand-alone product: a tool that can significantly augment and broaden the capabilities of existing sequence specific double-stranded DNA nuclease products like CRISPR, TALEN and ZFN. This RACeR technology edits and repairs genes with high specificity and with efficiencies up to 3000 times better than CRISPR-Cas9 alone.
Inven2 AS seeks licensees of the technology.
Currently, CRISPR and related tools, favor the error prone non-homologues end-joining (NHEJ) to repair induced DNA breaks; therefore, CRISPR-Cas9 is principally and easily used to create errors causing gene deletions and knock-outs. The current recombinases used are not efficient at incorporating foreign DNA which makes homology dependent repair (HDR) practically impossible. However by supplying an optimized variant of recombinases (RACeR) with Cas9 (or other double-stranded nucleases) and a homologous recombination substrate we see increased levels of HDR and an increase to 60-70 % efficacy in targeting repair or sequence insertions.
A provisional patent application protecting the invention was filed June 17 th 2016 and followed by a PCT application in June 2017.